10 / 140
132
15. Cook NR, Buring JE, Ridke PM, The effect of including C-reactive
protein in cardiovascular risk prediction model for women. Ann Intern
Med 2006;145:21-9.
16. Wong ND, Pio J, Valencia R, Thakal G. Distribution of C reactive and its
relation to risk factors and coronary heart disease risk estimation in the
National Health and Nutrition Examination Survey (NHANES) III. Prev
Cardiol 2001; 4:109-14.
17. Ridke PM, Buring JE, Cook NR, Rifai NR. C-reactive protein, metabolic
syndrome, and risk of incident cardiovascular events: an8 year followup of
14719 initially healthy America women. Circulation 2003;107: 391-7.
18. Spencer EA, Pirie KL, Stevens RJ, et al. For the Million Women Study
Collaborators. Diabetes and modifiable risk factors for cardiovascular
disease: The prospective Million Women Study. Eur J Epidemiol
2008;23:793-9.
19. Kanaya AM, Grady D, Barret-Connor E. Explaning the sex difference in
coronary heart disease mortality among patients with type 2 diabetes
mellitus: a meta-analisis. Arch Intern Med 2002;162:1737-45.
20. Kunstmann S, Gainza D. Dislipidemia en la mujer: Diagnostico,
clasificación y manejo. Rev. Medica Clínica Las Condes, 2009;20
(1):47-52.
21. Ogden CL, Carrol MD, Curtin LR, MacDowel MA Tabak CJ, Flegal KM.
Prevalence of overweight and obesity in the United States, 1999-
2004. JAMA 2006; 295:549-55.
22. McTigue K,Larson JC, Valosky A el al. Mortality and cardiac and vascular
outcomes in extremely obese women. JAMA 2006; 296:79-86.
23. Mendelshon M and Karas R. The protective effects of estrogens on the
cardiovascular system. N Engl J Med 1999; 340 (23) : 1801-11.
24. Arteaga E. Riesgo cardiovascular en el Climaterio. En: Consenso en
Climaterio 2001. Una recomendación fundamentada. Eds. E Arteaga,
P Contreras y O González. Ediciones Sociedad Chilena de Climaterio.
Editorial Bywaters, Santiago 2001 pp 61-73.
25. Hulley S, Grady D, Bush T, et al. for the Heart and Estrogen-progestin
Replacement Study (HERS) Research Group.. Randomized trial of
estrogen plus progestin for secondary prevention of coronary heart
disease in postmenopausal women. JAMA. 1998; 280:605-13.
26. Grady D, Herrington D, Bittner V, et al. for HERS Research Group.
Cardiovascular disease outcomes during 6.8 years of hormone therapy:
Heart and Estrogen/ progestin Replacement Study follow-up (HERS II).
JAMA 2002; 288: 49-57.
27. Kanaya AM, Herrington D,Vittinghoff E, et al. Glycemic effects of
postmenopausal hormone therapy: The Heart and Estrogen/progestin
Replacement Study. A randomized, double-blind, placebo-controlled
trial. Ann Intern Med. 2003;138:1-9.
28. Herrington DM, Vittinghoff E, Lin F, et al. Statin therapy cardiovascular
events, and total mortality in the Heart and Estrogen/Progestin
Replacement Study (HERS). Circulation 2002; 105:2962-7.
29. Writing Group for the Women’s Health Initiative Investigators.. Risks
and benefits of estrogen plus progestin in healthy postmenopausal
women. Principal results from the Women’s Health Initiative
randomized controlled trial. JAMA. 2002; 288: 321-33.
30. The Women’s Health Initiative Steering Committee. Effects of
conjugated equine estrogen in postmenopausal women with
hysterectomy. The Women’s Health Initiative randomized controlled
trial. JAMA 2004; 291:1701-12.
31. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and
coronary-artery calcification WHI-Coronary Artery Calcium Study
(WHI-CACS). New Engl J Med 2007; 356: 2591-2602.
32. Grodstein F, Manson JE, Stampfer MJ.. Hormone therapy and coronary
heart disease: The role of time since menopause and age at hormone
initiation. J Women’s Health. 2006;15: 35-44.
33. Salpeter SR, Walsh JME, Greyber E, Salpeter EE.. Brief Report: Coronary
heart disease events associated with hormone therapy in younger and
older woman. A meta-analysis. J Gen Intern Med. 2006; 21:363-6¬¬
34. Straczek C, Oger E, De Jonage-Canonico MBY, et al, for the Estrogen
and Thromboembolism Risk (ESTHER) Study Group. Circulation.
2005;112:3495-500
35. Harman SM, Black D, Naftolin F, Brinton EA, Budoff M, et al. Arterial
Imaging outcomes and cardiovascular risk factors in recently
menopausal women KEEPS. Ann. Intern Med 2014; July,1-16.
36. US Food and Drug Administration. FDA Updates: hormone therapy
information for postmenopausal women (2004). www.fda.gov/bbs/
topic/NEWS/2004/ NEW01022.html
37. The Board of Trustees of the North American Menopause Society.
Estrogen and progestogen use in postmenopausal women: 2010
position statement of The North American Menopause Society.
Menopause 2010;17(2) :242-255.
38. Ng V G, Meller S, Shetty S, Lansky A. Diagnosing and characterizing
coronary artery disease in women: Developments in noninvasive and
invasive imaging techniques. J. Cardiovascular Trans Res.2013; 6:
740-751.
[REV. MED. CLIN. CONDES - 2015; 26(2) 127-132]